Jupiter Neurosciences (NASDAQ:JUNS) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Jupiter Neurosciences (NASDAQ:JUNS) issued its earnings results on Thursday. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01), FiscalAI reports. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.23 million.

Jupiter Neurosciences Price Performance

Jupiter Neurosciences stock traded down $0.01 during mid-day trading on Friday, reaching $0.34. The stock had a trading volume of 40,053 shares, compared to its average volume of 88,968. The company has a market capitalization of $12.26 million, a price-to-earnings ratio of -1.25 and a beta of 2.16. The company has a 50-day moving average price of $0.38 and a two-hundred day moving average price of $0.78. Jupiter Neurosciences has a one year low of $0.31 and a one year high of $3.33.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Jupiter Neurosciences currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Jupiter Neurosciences

A hedge fund recently raised its stake in Jupiter Neurosciences stock. Geode Capital Management LLC increased its position in Jupiter Neurosciences, Inc. (NASDAQ:JUNS) by 27.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,641 shares of the company’s stock after purchasing an additional 28,826 shares during the period. Geode Capital Management LLC owned approximately 0.39% of Jupiter Neurosciences worth $135,000 at the end of the most recent reporting period.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.